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Background: Ischemia reperfusion (IR) injury is a complex phenomenon that leads to organ dysfunction and causes 
primary liver failure following liver transplantation. We investigated whether an intravenous administration of 
magnesium before reperfusion can prevent or reduce IR injury. 
Methods: Fifty-nine living donor liver transplant recipients were randomly assigned to an MG group (n = 31) or an 
NS group (n = 28). Each group was also divided in two groups based on the preoperative magnesium levels (normal: 
≥ 0.70 mmol/L, low: < 0.70 mmol/L). The MG groups received 25 mg/kg of MgSO4 mixed in 100 ml normal saline 
intravenously before reperfusion and the NS groups received an equal volume of normal saline. The levels of lactate, 
pH, arterial oxygen tension, and base excess were measured to assess reperfusion injury at five specific times, 
which were 10 min after the beginning of anhepatic phase, and 10, 30, 60 and 120 min after reperfusion. To evaluate 
postoperative organ function, the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total 
bilirubin and creatinine levels were measured at preoperative day 1, postoperative day 1 and 5.
Results: The blood lactate levels were significantly lower at 10, 30, 60 and 120 min after reperfusion in the MG groups 
compared to the NS groups. In addition, significantly higher blood lactate levels were observed in the NS group with 
preoperative hypomagnesemia than in MG groups. 
Conclusions: Magnesium administration before reperfusion of liver transplantation significantly reduces blood 
lactate levels. These findings suggest that magnesium treatment may have protective effects on IR injury during living 
donor liver transplantation. (Korean J Anesthesiol 2011; 60: 408-415)
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Introduction
    With advances in critical care management, immuno-
suppression and surgical techniques, liver transplantation has 
become one of the most effective treatments for acute or chronic 
liver failure [1]. In Korea, living donor liver transplantation 
(LDLT) has been more frequently performed than orthotopic 
liver transplantation because of the critical shortage of cadaveric 
donor organs [2]. During liver transplantation, ischemia 
reperfusion (IR) injury occurs after hepatic vascular clamping 
and reperfusion of the grafted liver. IR injury is a phenomenon 
that hypoxic cellular damage is aggravated following the 
restoration of oxygen delivery and it may be a major cause of 
primary liver failure after liver transplantation [3-5].
    The process of IR injury after reperfusion of the grafted 
liver has been divided into two phases [4,5]. The early phase 
(< 2 hours after reperfusion) involves abnormal increases in 
intracellular calcium concentration, and generation of reactive 
oxygen species by Kupffer cells, which results in subsequent 
hepatocyte injury and death. The late phase of liver injury (> 6 
hours after reperfusion) is an inflammatory disorder mediated 
by recruited neutrophils. This cellular response to ischemia and 
reperfusion can lead to a systemic inflammatory response and 
subsequent cellular damage. Thus, there have been many efforts 
to reduce or prevent IR injury, including surgical interventions, 
pharmacologic agents and gene therapy, but few treatments are 
currently available. 
    IR injury also occurs in myocardial infarction, ischemic 
spinal cord injury and stroke. Recent experiments have shown 
protective effects of magnesium to reduce the reperfusion injury 
of these conditions [6-9]. The intravenous administration of 
magnesium during coronary occlusion has caused a significant 
reduction in myocardial infarct size [6]. This is because 
magnesium provide cellular protection during ischemia and 
reperfusion by stabilizing the cellular transmembrane potential, 
suppressing excessive calcium influx and reducing cellular 
energy demand [10]. Magnesium administration also enhances 
electrophysiological and neurobehavioral recovery and reduces 
brain infarction after cerebral ischemia-reperfusion [8]. 
Kaplan et al. [9] reported that the use of magnesium may have 
protective effects on reperfusion injuries of the spinal cord in 
rabbits.
    Despite these advances, little is known about the effects of 
magnesium on hepatic IR injury during liver transplantation. 
The primary aim of this study was to evaluate the effects of 
intravenous magnesium infusion before reperfusion of the 
grafted liver by employing blood lactate levels and some clinical 
parameters, since the intraoperative changes in the blood 
lactate levels after hepatic allograft reperfusion served as an 
accurate predictor of the initial graft function in LDLT [11]. The 
secondary objective was to examine the postoperative organ 
function to detect delayed effects of magnesium.
Materials and Methods
    The study was approved by the Institutional Review Board and 
written informed consent was obtained from all the patients. 
We studied adult patients who were scheduled for elective 
LDLT using the right hepatic lobe. The exclusion criteria were 
pediatric patients, re-transplantation and patients with renal 
dysfunction or cardiovascular disease. Liver transplantation 
was always performed by the same team of surgeons and 
anesthesiologists using the same surgical techniques.
    Demographic data, Child-Turcotte-Pugh (CTP) classification 
[12], United Network for Organ Sharing (UNOS) status [13], 
Model for End-stage Liver Disease (MELD) score [14] and the 
diagnosis were obtained from the medical records. Patients 
were randomized to receive magnesium solution (MG group, n 
= 31) or normal saline (NS group, n = 30). Each group was also 
divided in two groups as the normal and the low group based 
on the preoperative magnesium levels (normal group: ≥ 0.70 
mmol/L, low group: < 0.70 mmol/L). 
    Allocation concealment was ensured using sequentially 
numbered sealed opaque envelopes. Immediately after arrival 
of the patient in the operating room, an anesthesiologist not 
involved in the study opened the envelopes and prepared the 
study solution outside the operating room. 
    Thirty minutes after the beginning of the anhepatic phase, the 
patients received a magnesium solution (25 mg/kg of MgSO4 
mixed in 100 ml of normal saline) or an equivalent volume 
of normal saline over 20 min. Other anesthesiologist, who 
was blinded to the group assignment, performed intravenous 
administration of the study solution and assessed study 
outcomes. 
    Administration of fluid, vasopressors and inotropes were 
guided by hemodynamic monitoring and clinical parameters 
(central venous pressure: 8 to 10 mmHg, systolic blood pressure 
> 90 mmHg, heart rate < 100 beat/min, pulmonary artery 
wedge pressure: 10 to 14 mmHg, urine output: 0.5 to 1 ml/
kg/hr). Packed red blood cells were transfused to keep the 
hematocrit at 30%. Administration of fresh frozen plasma and 
platelets were based on clinical findings by inspection of the 
surgical field and the results of thromboelastography. Platelets 
were given if platelet count decreased to < 50 × 10
9/L. Calcium 
chloride and sodium bicarbonate were used to correct low 
ionized Ca
2+ levels (Ca
2+ < 0.9 mmol/L) and metabolic acidosis 
(pH < 7.2 and base excess < -10 mmol/L), respectively.
    All patients who remained intubated after surgery were 
transferred directly to the intensive care unit (ICU) for 
postoperative care. Lengths of stay in the ICU were recorded for 410 www.ekja.org
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all patients. 
    The plasma total magnesium concentrations were measured 
four times: preoperatively (one day before surgery: the base-
line), 10 minutes after the beginning of the anhepatic phase, 10 
minutes after reperfusion and postoperative day 1 (POD 1). 
    Arterial blood samples were analyzed after anesthesia 
induction, 10 minutes after the beginning of the anhepatic 
phase and 10, 30, 60 and 120 minutes after reperfusion using a 
blood gas analyzer (ABL800 FLEX, Radiometer, Copenhagen, 
Denmark). The measured variables included arterial pH, 
arterial oxygen tension (PaO2), base excess, lactate and glucose 
as indicators of ischemic injury and perfusion markers to 
evaluate the effects of magnesium on reperfusion injury. The 
mean arterial pressure (MAP) was recorded at the same time. 
Blood lactate levels were measured using ABL800 FLEX that 
employs a technique based on spectrophotometry analysis 
adopting a lactate dehydrogenase (LDH) method. The precision 
of this method of lactate measurement has been previously 
validated [15-17].
    For estimating postoperative organ dysfunction, serum 
concentrations of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin and creatinine were 
measured preoperatively, as well as on POD 1 and POD 5.
    The sample size estimation was based on the mean value of 
the blood lactate levels from our preliminary study. Twenty 
five patients per group were required to show a 50% difference 
in blood lactate levels, with a two sided α of 0.05 and a β of 
0.2 (power = 80%). All the analyses were performed using 
SAS software version 9.1 (SAS Institute, Cary, NC, USA) and 
the results were expressed as means ± standard deviations. 
Continuous variables were compared by repeated measures 
analysis of variance (ANOVA). Where post hoc testing was 
applied, a Bonferroni adjustment was used and P value was 
corrected. Simple comparisons of age, weight, and height were 
made by using one-way ANOVA. Categorical variables were 
compared by using the Chi-square test or Fisher’s exact test. P 
values of < 0.05 were considered statistically significant. 
Results
    Sixty-one patients were enrolled in this study and two patients 
in the NS groups were excluded because of postoperative 
bleeding and re-operation. Distributions of patients and clinical 
profiles are shown in Table 1. The demographic characteristics, 
CTP classification, UNOS status and MELD score did not differ 
among the groups. Hepatitis B virus (HBV) or hepatitis C virus 
(HCV) related liver cirrhosis and hepatocellular carcinoma were 
the most common liver diseases in all groups. Intraoperative 
transfusion requirement and the length of ICU stay were not 
different among the groups.
    The magnesium concentrations increased significantly 
after magnesium administration in the magnesium-treated 
Table 1. Demographic Data and Clinical Profiles Including Transfusion Amounts in Living Donor Liver Transplantation 
Normal 
(preoperative magnesium levels ≥ 0.70 mmol/L)
Low 
(preoperative magnesium levels < 0.70 mmol/L)
NS group
(n = 21)
MG group
(n = 21)
NS group
(n = 7)
MG group
(n = 10)
Age (yr)
Sex (M/F)
Body weight (kg)
Height (cm)
UNOS status (1/2/3) 
CTP classification (A/B/C) 
MELD score
Diagnosis 
    HBV or HCV related liver disease
    Alcoholic liver disease
    Acute hepatic failure
    Primary biliary cirrhosis
    Autoimmune hepatitis
PRC (units)
FFP (units)
Platelet (units)
ICU stay (d)
48.3 ± 9.3
15/6
66.0 ± 8.9
169.8 ± 8.2
0/14/7
5/7/9
16.9 ± 7.7
19
0
0
2
0
11.2 ± 3.1
10.5 ± 5.0
3.4 ± 3.2
6.4 ± 0.3
46.2 ± 8.2
12/9
66.3 ± 5.9
169.9 ± 4.6
0/13/8
5/10/6
16.1 ± 5.2
18
0
0
2
1
10.3 ± 3.3
9.4 ± 3.8
3.2 ± 2.5
6.5 ± 0.6
47.8 ± 10.8 
5/2
69.2 ± 10.0
168.3 ± 5.5
0/4/3
1/3/3
17.3 ± 7.9
6
1
0
0
0
13.5 ± 5.6 
12.4 ± 5.5
3.3 ± 4.0
6.7 ± 0.2
50.4 ± 5.5
7/3
63.8 ± 8.5
164.6 ± 6.1
0/5/5
1/5/4
16.4 ± 5.4
8
1
1
0
0
12.0 ± 4.6
10.0 ± 3.8
2.9 ± 3.5
6.8 ± 0.3
Values are expressed as mean ± SD or number of patients. UNOS status: United Network for Organ Sharing status, CTP classification: Child-
Turcotte-Pugh classification, MELD: Model for End-stage Liver Disease, HBV: Hepatitis B virus, HCV: Hepatitis C virus, PRC: packed red cell, 
FFP: fresh frozen plasma, ICU stay: length of stay in intensive care unit. No significant differences among the groups.411 www.ekja.org
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groups (Normal-MG and Low-MG group) compared to the 
NS groups (Normal-NS and Low-NS group, Fig. 1). At POD 
1, the magnesium concentrations decreased but the levels 
were within the normal range in magnesium-treated groups. 
However, the magnesium levels in the NS groups constantly 
decreased and the levels fell below the normal range at POD 1 
(Fig. 1).
    The blood lactate levels were similar in all groups at baseline, 
but significantly reduced at 10, 30, 60 and 120 min after 
reperfusion in the magnesium-treated groups. However there 
was a continuous elevation of blood lactate levels in the NS 
groups. In addition, significantly higher blood lactate levels 
were observed in Low-NS group than magnesium-treated 
groups (Fig. 2). 
    After reperfusion, the pH values significantly decreased 
compared to the anhepatic phase. However, there were no 
differences in pH, base excess, PaO2 and MAP among the 
groups (Fig. 3). 
    At POD 1, the serum AST, ALT, total bilirubin and creatinine 
levels significantly increased compared to the preoperative 
values in all groups. These parameters decreased at POD 5, but 
there was no difference among the groups (Fig. 4).
Discussion
    The purpose of this study was to evaluate whether admini-
stration of magnesium has protective effects against reperfusion 
injury in liver transplantation. During ischemia and reperfusion 
of liver, ATP depletion and endothelial injury cause an increase 
in anaerobic metabolism that leads to lactate accumulation [18]. 
Our results showed that the blood lactate levels after reperfusion 
were significantly lower in the MG groups compared to the NS 
groups.
    The blood lactate level is often used clinically as a marker of 
anaerobic metabolism and may represent inadequate tissue 
perfusion. Elevated blood lactate levels significantly correlated 
with the severity of hypoperfusion, hypoxia and severe ischemic 
damage of the liver [19]. During ischemia and reperfusion, 
injury to the endothelial cell resulted in inhibition of pyruvate 
dehydrogenase and consequently caused anaerobic glycosis, 
glycogenolysis, and lactate accumulation [20,21]. There are two 
major mechanisms for hyperlactatemia in liver transplantation: 
the shift to anaerobic glycolysis due to tissue hypoperfusion and 
the decrease of lactate clearance by insufficient liver function 
[22]. 
Fig. 1. Changes in magnesium concentration during living donor 
liver transplantation. The magnesium concentrations significantly 
increased after magnesium administration in Normal-MG and 
Low-MG group. Preop: preoperative 1 day, Anhepatic + 10 min: 
10 minute after the beginning of anhepatic phase, Reperfusion + 
10 min: 10 minute after reperfusion, POD 1: postoperative 1 day. 
The normal range of serum magnesium concentration is 0.70 to 
1.10 mmol/L. Normal-NS: NS group with preoperative magnesium 
levels ≥ 0.70 mmol/L, Normal-MG: magnesium-treated group with 
preoperative magnesium levels ≥ 0.70 mmol/L, Low-NS: NS group 
with preoperative magnesium levels < 0.70 mmol/L, Low-MG: 
magnesium-treated group with preoperative magnesium levels 
< 0.70 mmol/L. Data are the mean ± SD. *P < 0.05 compared with 
Normal-NS group, 
†P < 0.05 compared with Low-NS group. 
‡P < 0.05 
compared with Preop by Bonferroni correction. 
Fig. 2. Changes in blood lactate levels before and after reperfusion 
in living donor liver transplantation. Significantly higher blood 
lactate levels were observed in the Low-NS group compared to 
magnesium-treated groups after reperfusion. Normal-NS: NS group 
with preoperative magnesium levels ≥ 0.70 mmol/L, Normal-MG: 
magnesium-treated group with preoperative magnesium levels ≥ 0.70 
mmol/L, Low-NS: NS group with preoperative magnesium levels 
< 0.70 mmol/L, Low-MG: magnesium-treated group with pre  ope-
rative magnesium levels < 0.70 mmol/L. Data are the mean ± SD. 
*P < 0.05 compared with Normal-MG group, 
†P < 0.05 compared 
with Low-MG group. 412 www.ekja.org
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    In previous studies [11,18], hyperlactatemia was shown to 
possess prognostic significance in liver transplantation. The 
lactate levels rose during the preanhepatic and anhepatic 
phases and peaked at 10 min after reperfusion. Following 
reperfusion, a constant decrease in the lactate level was 
recorded in the group with a good immediate graft function [18]. 
Some investigators have suggested the intraoperative changes 
in the blood lactate levels after hepatic allograft reperfusion 
served as an accurate predictor of the initial graft function in 
LDLT [11]. Therefore, we measured blood lactate levels before 
and after reperfusion of the grafted liver to evaluate the effects 
of magnesium treatment on IR injury.
    Magnesium is an important cofactor for many enzymatic 
reactions. It is essential for the production and functioning of 
ATP, therefore preserves energy-dependent cellular activity, 
particularly during ischemic episodes. Magnesium also blocks 
calcium entry into the cell by acting on voltage receptor 
and receptor-operated membrane channels [10]. Since 
calcium overload has an important role in the pathogenesis 
of reperfusion injury [5], magnesium may provide cellular 
protection during ischemia. 
    Patients with end-stage liver disease usually show hypoma-
Fig. 3. Changes of physiological parameters before and after reperfusion in living donor liver transplantation. (A) pH, (B) PaO2, (C) MAP, (D) 
Base excess. After reperfusion, pH values were significantly decreased compared to anhepatic + 10 min. No significant difference was observed 
between the groups. Data are the mean ± SD. Anhepatic + 10 min: 10 min after the beginning of the anhepatic phase, Reperfusion + 10, 30, 
60 and 120 min: 10, 30, 60 and 120 min after reperfusion, MAP: mean arterial pressure. Normal-NS: NS group with preoperative magnesium 
levels ≥ 0.70 mmol/L, Normal-MG: magnesium-treated group with preoperative magnesium levels ≥ 0.70 mmol/L, Low-NS: NS group with 
preoperative magnesium levels < 0.70 mmol/L, Low-MG: magnesium-treated group with preoperative magnesium levels < 0.70 mmol/L. *P < 
0.05 compared with Anhepatic + 10 min by Bonferroni correction. 413 www.ekja.org
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gnesemia before liver transplantation either due to decreased 
intake and gastrointestinal absorption of magnesium, or to 
increased excretion of magnesium caused by the treatments of 
diuretics for ascites [23-25]. A significant decrease of the plasma 
magnesium concentration occurs during both dissection and 
anhepatic phase in orthotopic liver transplantation [24]. In 
this study, magnesium levels constantly decreased during liver 
transplantation in NS groups. Since magnesium is important 
for the maintenance of cardiovascular homeostasis and 
neurological stability, any acute changes in the magnesium 
levels must be detected and treated promptly [25]. 
    However, the over-normalization of the magnesium levels 
must be cautiously avoided. Hypermagnesemia can cause 
peripheral vasodilation, leading to worsening of hypotension 
during the reperfusion phase in liver transplantation. In 
addition, magnesium is a powerful cerebral vasodilator that 
may be deleterious to patients with hepatic encephalopathy 
and increased intracranial pressure [24]. Thus, magnesium 
supplementation should be titrated with plasma magnesium 
levels to avoid hypermagnesemia and the associated risk of 
unwanted side effects. Magnesium is usually given in amount of 
2 g intravenously over 30 min to correct hypomagnesemia [10]. 
In the second Leicester Intravenous Magnesium Intervention 
Trial (LIMIT-2) [7], patients with acute myocardial infarction 
randomly received magnesium 2 g or placebo over 5 min, 
before thrombolytic therapy, followed by 16 g as infusion 
over the next 24 h. Serum magnesium concentrations were 
approximately doubled for 24 h and returned to normal by 48 
h. In a previous study [26], when 1.5 g of magnesium sulfate 
mixed in 100 ml of normal saline was infused, the magnesium 
Fig. 4. Changes of serum AST, ALT, total bilirubin and creatinine levels before and after living donor liver transplantation. All parameters were 
observed to significantly increase at POD 1 and decrease at POD 5, but there was no difference between the groups. Normal-NS: NS group with 
preoperative magnesium levels ≥ 0.70 mmol/L, Normal-MG: magnesium-treated group with preoperative magnesium levels ≥ 0.70 mmol/L, 
Low-NS: NS group with preoperative magnesium levels < 0.70 mmol/L, Low-MG: magnesium-treated group with preoperative magnesium 
levels < 0.70 mmol/L. AST: aspartate aminotransferase, ALT: alanine aminotransferase. Preop: preoperative value (one day before surgery), 
POD 1: postoperative 1 day, POD 5: postoperative 5 day. *P < 0.05 when compared with Preop by Bonferroni correction.414 www.ekja.org
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concentration increased within the normal range during 
LDLT. From these results, we selected the dose (25 mg/kg) of 
magnesium sulfate because the administration of 1.5 to 2 g of 
magnesium to patients of 60 to 70 kg corresponds to 25 mg/kg. 
Our results showed that this dose of magnesium was adequate 
to maintain the normal range of the magnesium levels without 
inducing hypermagnesemia. 
    Magnesium deficiency is associated with enhanced lipid 
peroxidation and production of reactive oxygen species 
during ischemia [27-29]. In another study [30], magnesium 
supplementation markedly inhibited lactate production and 
concomitant lipid peroxidation after cerebral ischemia. In this 
study, we observed higher blood lactate levels after reperfusion 
in the NS group with preoperative hypomagnesemia than those 
with normal preoperative magnesium levels. In magnesium-
treated groups, blood lactate levels were significantly lower at 
10, 30, 60, and 120 min after reperfusion than in the NS group 
with preoperative hypomagnesemia. In addition, the MAP 
values, which are probably the most useful parameter to assess 
organ perfusion, were adequately maintained in all groups for 
2 h after reperfusion. Based on these results, the differences 
in lactate levels were probably not due to tissue perfusion, but 
rather, correlated with magnesium administration.
    The pH values significantly decreased after reperfusion, 
possibly due to the acid load entering the systemic circulation 
from the ischemic liver, despite attempts to compensate for this. 
The fall in pH at reperfusion was associated with a concomitant 
rise in blood lactate levels. However, there were no differences 
in the values of pH and base excess among the groups for 120 
min after reperfusion. Thus, it is difficult to conclude that the 
magnesium employed in the present study has protective 
effects on these parameters associated with reperfusion injury. 
    We also compared postoperative AST, ALT, total bilirubin 
and serum creatinine levels to detect the delayed effects of 
magnesium on organ injury. These parameters significantly 
increased at POD 1 and decreased at POD 5, but there was no 
difference among the groups. 
    In cerebral IR injury, magnesium treatment significantly 
suppressed the increase of lactate concentrations, and improved 
EEG changes when compared with the untreated group [30]. 
The neuroprotective effects of magnesium may be explained 
as follows: magnesium is a well-known N-methyl-D-aspartate 
(NMDA) receptor blocker and may prevent intracellular 
accumulation of calcium ion. Magnesium may decrease 
endothelial and neuronal reperfusion injuries by directly 
inhibiting lipid peroxidation and by preventing glutathione 
depletion, regulate ATP concentrations and regenerate ATP after 
ischemia and reperfusion [31]. In the present study, magnesium 
treatment for hepatic IR injury attenuated the increase of lactate 
levels, but this result was not correlated with the protective 
effects of magnesium on postoperative organ function. This was 
most likely because such neuroprotective effects of magnesium 
may not be important in protecting hepatic IR injury. 
    This study had some limitations. First, the dose of magnesium 
(25 mg/kg) was relatively lower than in other studies. We 
anticipate that higher doses of magnesium would have 
protective effects on postoperative organ function. Second, we 
did not measure any cytokines or chemokines, such as tumor 
necrosis factor α, interleukin 1 and 6, which are the mediators of 
hepatic IR injury and give further information about IR injury. 
Third limitation is that the patients in this study were relatively 
healthy recipients because they were scheduled for elective 
LDLT. Also, every patient was controlled or supported with 
drugs and fluid administration to maintain stable hemodynamic 
and metabolic states during liver transplantation. These factors 
may contribute to observing no significant differences in 
postoperative organ function among the groups.
    In conclusion, we determined that magnesium treatment is 
associated with reducing blood lactate levels after reperfusion 
of grafted liver. This result is consistent with those of previous 
studies [29,30] showing that magnesium administration 
inhibit lactate production after IR injury. However, there were 
no differences in the pH, base excess, PaO2, postoperative 
liver enzymes, and creatinine between the groups. Therefore, 
we recommend that further studies with optimized dose 
of magnesium are needed to investigate the precise and 
affirmative effects of magnesium on hepatic IR injury. 
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